INVESTIGATIVE REPORT | Healthcare & Industry Analysis
Executive Overview
For decades, the medical establishment treated half of the global population as an afterthought—or worse, a statistical anomaly. Textbooks were modeled primarily around the standard male physiological baseline, pharmaceuticals were tested predominantly on men, and complex conditions unique to female biology were routinely minimized, misdiagnosed, or relegated to the psychological realm.
Today, however, the narrative appears to be transforming. Women’s health—long dismissed by institutional investors as a niche, unmarketable sector—is seemingly having its moment. Driven by a wave of vocal advocacy, destigmatization, and digital-first innovation, private equity firms, venture capitalists, and major corporate healthcare players have flooded the market with capital. Between 2020 and 2025, investors poured nearly $60 billion into women’s health initiatives, sparking widespread declarations that a renaissance in medical equity had finally arrived.
Yet, behind the soaring valuation metrics and the influx of boardroom capital lies a stark and unsettling reality. According to a landmark report released today by healthcare strategy firm Langrand, titled "Still Waiting," 73% of women report feeling dismissed, overlooked, or invalidated in healthcare settings purely because of their gender.
This survey of 1,000 U.S. women between the ages of 18 and 44 lays bare a profound systemic paradox. While Wall Street and Silicon Valley celebrate record-breaking investments in femtech and reproductive care, the everyday patient experience remains plagued by institutional neglect. The data reveals an alarming gulf between the macroeconomic enthusiasm of the boardroom and the sobering, dismissive reality of the clinical exam room.
As the healthcare industry grapples with this disconnect, questions loom large: Where is the $60 billion actually going? Why is patient-level transformation lagging so far behind financial investment? And what structural reforms are necessary to turn boardroom metrics into tangible clinical relief?
Detailed Chronology: The Evolution of the Women’s Health Movement
To understand the current crisis, one must trace the winding, often frustrating history of how women’s health evolved from a medical blind spot into a multi-billion-dollar asset class.
The Pre-2020 Era: The Medical Baseline of Exclusion
For generations, modern medicine operated under a deeply flawed premise: that male physiology served as the universal proxy for the human body. Until the National Institutes of Health (NIH) Revitalization Act of 1993, women of childbearing potential were routinely excluded from early-phase clinical drug trials out of an abundance of caution regarding potential fetal harm.
The consequences of this exclusion were catastrophic. Drugs metabolized differently in women frequently led to adverse side effects, unexpected toxicities, and delayed diagnoses. Diseases that disproportionately or uniquely affected women—such as endometriosis, autoimmune disorders, and chronic pelvic pain—suffered from a chronic lack of research funding, leaving physicians ill-equipped to treat them effectively.
2020–2021: The Pandemic Catalyst and the Birth of "Femtech"
The modern investment boom began taking shape amid the crucible of the COVID-19 pandemic. As telehealth surged and venture capital sought resilient, high-growth sectors, a new generation of entrepreneurs—many of them women—began building digital health companies addressing menstruation, fertility, menopause, and maternal mortality.
Coined broadly as "femtech," this sector started attracting early-stage venture funding. Investors woke up to a massive, underserved demographic that controlled upwards of 80% of consumer healthcare purchasing decisions. However, during this initial phase, investments were largely concentrated in consumer-facing apps, fertility trackers, and direct-to-consumer telemedicine services, rather than core clinical research or complex disease therapeutics.
2022–2023: Maturation, Scaling, and Institutional Recognition
As the macroeconomic climate tightened in 2022 and 2023, funding for speculative startups contracted. However, women’s health demonstrated remarkable resilience. Private equity firms and corporate healthcare giants recognized that women’s health was not a temporary trend, but a structurally undervalued market.
During this period, investments shifted from simple mobile applications to more complex healthcare delivery models, diagnostics, and therapeutics. Major pharmaceutical companies began acquiring specialized startups, and academic medical centers established dedicated women’s health innovation hubs. Total capital deployment crossed multi-billion-dollar thresholds year after year, culminating in a cumulative investment approaching $60 billion by 2025.
2024–2025: The Awakening and the "Still Waiting" Reality
By 2025, the sheer volume of capital entering the sector forced a reckoning. Stakeholders began asking fundamental questions: Has this historic injection of funds actually changed patient outcomes?
Enter the Langrand "Still Waiting" report. Commissioned specifically to evaluate whether financial investments had translated into measurable, positive changes for everyday patients, the study shattered the self-congratulatory consensus of the healthcare investment community. By demonstrating that nearly three-quarters of women still feel dismissed by their healthcare providers, the report acted as an urgent wake-up call, proving that funding a sector is not the same as fixing a system.
Supporting Context & Metrics: Analyzing the $60 Billion Gap
The intersection of billions of dollars in capital investment and a 73% patient dissatisfaction rate highlights a profound systemic failure in how healthcare innovation is prioritized, funded, and distributed.
Where Did the Money Go?
To understand why patients feel left behind, one must analyze where the nearly $60 billion was deployed between 2020 and 2025:
- Consumer Health & Fertility Apps (approx. 35%): A significant portion of early venture capital went toward fertility tracking, pregnancy monitoring apps, and direct-to-consumer fertility clinics. While valuable for family planning, these solutions primarily serve affluent, tech-enabled consumers and do little to address chronic illnesses, systemic bias, or acute care disparities.
- Telehealth and Virtual Care Platforms (approx. 25%): Virtual care models expanded access to general practitioners and specialists, helping bridge geographic gaps. However, many of these platforms operate on compressed visit times that can exacerbate the tendency of providers to rush through complex or misunderstood symptoms reported by female patients.
- Diagnostics and Therapeutics (approx. 40%): Though capturing a sizable share, funding for deep clinical research, diagnostic tools for conditions like endometriosis and polycystic ovary syndrome (PCOS), and novel therapeutics has faced longer development timelines. Consequently, many of these breakthroughs have yet to reach the commercial exam room.
The Anatomy of Dismissal: What the Langrand Data Reveals
The Langrand survey of 1,000 U.S. women (aged 18–44) provides a granular look into the everyday friction points of the modern healthcare system. Key insights from the "Still Waiting" report include:
- The Gender Discount: 73% of respondents reported instances where they felt their physical pain, mental health concerns, or physiological symptoms were minimized, misattributed to anxiety, or ignored by medical professionals.
- The Diagnostic Odyssey: Women suffering from chronic, complex conditions reported enduring years of misdiagnoses—often being told their symptoms were "normal," stress-related, or psychosomatic—before receiving accurate medical evaluations.
- Demographic Disparities: The sense of alienation is frequently compounded for women of color, lower-income patients, and LGBTQ+ individuals, who face intersecting layers of systemic bias within clinical environments.
[Capital Influx: $60B (2020-2025)]
│
▼
[Venture Capital & PE Focus: Tech Apps, Direct-to-Consumer, Telehealth]
│
▼
[Systemic Clinical Lag: Outdated Training, Rushed Appointments, Bias]
│
▼
[Patient Reality: 73% of Women Feel Dismissed in Exam Rooms]This structural misalignment explains why massive financial inflows have failed to move the needle on patient trust. Wall Street measures success in return on investment (ROI), user acquisition, and EBITDA; patients measure success in being heard, receiving accurate diagnoses, and finding relief from chronic suffering.
Official Statements and Industry Perspectives
The release of the "Still Waiting" report has sparked intense debate among healthcare executives, venture capitalists, patient advocates, and clinicians.
Voices from the Investment Community
Venture capitalists who spearheaded the $60 billion wave defend their deployment of capital while acknowledging that the ecosystem is still in its infancy.
"We have built an incredible foundation over the last five years," notes a managing partner at a prominent health-tech venture fund. "Capital mobilization was step one. We proved to the market that women’s health is a massive, viable economic engine. But technology and capital alone cannot instantly rewrite decades of entrenched clinical culture. The infrastructure is being built, but changing what happens inside a traditional doctor’s office requires structural, systemic reform that goes far beyond software apps and digital health platforms."
Perspectives from Patient Advocates and Researchers
Advocates argue that the investment community has largely focused on low-hanging fruit—commodifying wellness and fertility—while underinvesting in systemic medical reform and complex disease research.
"For too long, the healthcare industry has treated women’s health as a niche market or a lifestyle category rather than a fundamental pillar of public health," says a leading women’s health advocate and researcher. "When 73% of women report feeling dismissed, it tells us that throwing money at tech startups without reforming medical education and provider training is fundamentally missing the point. A fancy app cannot compensate for a physician who refuses to believe a patient’s description of her own pain."
The Clinical Dilemma
Frontline healthcare providers point to systemic pressures within modern healthcare delivery—such as administrative burdens, short appointment windows, and outdated medical curricula—as primary drivers of patient alienation.
"Doctors are often working under extreme constraints, with as little as 10 to 15 minutes per patient," explains a practicing OB-GYN and clinical professor. "In that short window, if a clinician has not been adequately trained in the specific physiological presentations of female-centric diseases, it becomes far too easy to fall back on generalized assumptions or dismiss complex symptoms. We need deep institutional changes in how medical schools teach sex-and-gender-based medicine."
Future Outlook: Bridging the Chasm Between Boardroom and Exam Room
As the healthcare industry looks past the milestone of the $60 billion investment wave, the mandate for the future is clear: the focus must shift from financial accumulation to clinical transformation. Closing the chasm between boardroom optimism and exam-room reality will require coordinated action across multiple sectors.
1. Reforming Medical Education and Clinical Training
To eliminate the institutional bias highlighted in the Langrand report, medical schools and residency programs must overhaul their curricula. Sex- and gender-based biology must become a mandatory, core component of medical training. Clinicians must be educated on how diseases—ranging from cardiovascular conditions to autoimmune disorders—manifest differently in women, and trained to actively combat unconscious gender bias in clinical decision-making.
2. Directing Capital Toward Core Therapeutics and Diagnostics
Future investment strategies must pivot away from superficial consumer applications and concentrate heavily on deep tech, diagnostics, and therapeutics for misunderstood and neglected conditions. Diseases like endometriosis, chronic pelvic pain syndrome, perimenopausal neurology, and autoimmune disorders require rigorous scientific research and long-term capital commitment to deliver real breakthrough solutions.
3. Redesigning Healthcare Delivery Models
Health systems and payers must rethink the structural design of clinical encounters. Lengthening standard appointment times for complex complaints, incentivizing holistic listening over rapid patient throughput, and integrating multidisciplinary care teams can help restore trust between patients and providers.
4. Accountability and Patient-Centric Metrics
Moving forward, investors and healthcare executives must incorporate patient-reported outcome measures (PROMs) and qualitative satisfaction metrics into their evaluation criteria. Financial returns should no longer be the sole benchmark of success; the true test of an investment must be whether it tangibly improves the daily lived experience of the patient.
Conclusion
The injection of nearly $60 billion into women’s health between 2020 and 2025 represents an unprecedented financial milestone. It signaled a long-overdue acknowledgement that women are not a medical anomaly, but the cornerstone of global healthcare consumption and well-being.
Yet, as the Langrand "Still Waiting" report powerfully demonstrates, financial capital alone is not a panacea. When 73% of women continue to feel dismissed in healthcare settings, it becomes undeniably clear that the boardroom and the exam room are still operating in two entirely different worlds.
Bridging this gap is the defining challenge for the healthcare industry in the years ahead. Only by translating economic investment into rigorous clinical research, modernized medical education, and empathetic patient care can the industry finally deliver on the promise of true medical equity—ensuring that women no longer have to wait for the care they deserve.